Printer Friendly

MILES R&D EXPENDITURES TO BE $490 MILLION IN 1993

 PITTSBURGH, Feb. 18 /PRNewswire/ -- Miles Inc. said today that its expenditures on research and development will increase to about $490 million in 1993, up nearly 12 percent from the $438 million the company spent in 1992.
 "In the past year, we have made excellent progress toward establishing Miles as a leading chemicals, health care and imaging technologies company, but the ability to achieve our long-term goals is clearly tied to the productivity of our research and development programs," said President and Chief Executive Officer Helge H. Wehmeier. "Fortunately, we, and ultimately our customers, benefit significantly from the nearly $2 billion worldwide research programs of our parent company in Germany."
 Miles' R&D spending is concentrated in health care, polymers and coatings, agriculture, and imaging technologies.
 Among the most promising new products from the company's pharmaceutical research pipeline is Kogenate, which was developed to treat people with hemophilia. The Blood Products Advisory Committee of the Food and Drug Administration (FDA) unanimously agreed that Kogenate, a genetically engineered Factor VIII product, was shown to be safe and effective in treating patients with hemophilia; FDA approval is expected shortly.
 The biotechnology area holds great promise for Miles, according to Wehmeier. In addition to Kogenate, the company is studying the effects of Anti-TNF antibodies, a novel treatment for septic shock. Tumor Necrosis Factor, or TNF, is believed to play a central role in the development of the sepsis syndrome and shock. Company studies are determining the effect of administering monoclonal antibodies that neutralize TNF in improving patients' outcomes.
 Also in development is a successor to Miles' oral anti-infective Cipro, one of the 30 most prescribed drugs in the U.S. Studies have shown that the drug may have significant advantages, including expanded antibacterial coverage.
 Last year, Miles dedicated the second phase of its $130 million pharmaceutical research center in West Haven, Conn., home to the company's Pharmaceutical Division. The Miles Research Center, as it is called, employs more than 230 biologists, biochemists, chemists and scientific support staff in six scientific institutes.
 New in 1992 from Miles' Consumer Healthcare business was Mycelex-7, a product used to treat vaginal yeast infections. Introduced in June, this prescription-to-over-the-counter product earned a nearly 14 percent unit share by the end of the year.
 Miles is also one of the leading diagnostics companies in the world, with research carried out at both Tarrytown, N.Y., and Elkhart, Ind. During 1993, the company plans to begin marketing five new diagnostic systems. Among them is the Immuno I, a fully automated immunoassay analyzer that aids in the early diagnosis of thyroid disorders, infertility and infectious diseases. Another is the Glucometer Elite, a blood glucose testing product that will complement the company's Glucometer family of diabetes care systems. The Glucometer Elite provides greater convenience and accuracy by reducing patient involvement in testing procedures.
 Utilizing its 30 years experience in coatings resins, Miles is committed to being the leader in advancing the technology of polyurethane-based chemistry for the formulation, testing, and application of low-VOC (volatile organic compound) polyurethane-based coatings that retain high-performance characteristics. Today, the driving force in the paint and coatings industry is to reduce VOC emissions to comply with more stringent air pollution standards being established by the U.S. Environmental Protection Agency and state agencies. Miles is being proactive by setting as its goal lower- and solvent-free technology -- ultimately zero VOC. The company's top priority is the development of raw materials for waterborne and higher solids coating systems.
 In polymers, Miles is developing new recycling technologies for polyurethane materials, long considered unrecyclable. The new technologies include compression molding, adhesive pressing and glycolysis. There has also been a concerted effort to replace the chlorofluorocarbons (CFCs) in the blowing agents traditionally used for polyurethane foam products. This program has resulted in the introduction of new foam systems such as the one used to produce sag-resistant spoilers for autos. Other R&D activities include development of new reaction injection molding (RIM) products and energy-absorbing foams for automotive applications, as well as continuing quality improvements in the thermoplastic materials used for medical, optical and optical memory applications.
 Miles' Agriculture Division introduced a new, lower dosage clostridial injection to treat cattle for blackleg disease in 1992. And the division's Consumer Household Business launched a backyard insect repellent.
 In 1993, four crop protection and specialty products are in the final development phase: Folicur, a fungicide; Confidor, an insecticide; Aztec, a corn rootworm insecticide; and Merit, a grub control insecticide for the turf industry, to be introduced in 1994.
 In 1992, the company's Agfa Division provided professionals in the electronic prepress business with two significant new products: AccuSet, a state-of-the-art PostScript imagesetter, and a new generation of PostScript raster image processors (RIPs) that allow output of more pages in less time, boosting productivity.
 Miles is a Fortune 100 research-based company with major businesses in chemicals, health care and imaging technologies. Headquartered in Pittsburgh, Miles employs some 23,000 people at its operations throughout North America. In 1992, the company's sales were about $6.5 billion.
 -0- 2/18/93
 /CONTACT: Barry S. Cohen of Miles, 412-394-5504/


CO: Miles Inc. ST: Pennsylvania, Connecticut IN: CHM MTC SU:

DM -- PG001 -- 7763 02/18/93 10:11 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 18, 1993
Words:867
Previous Article:STANDARD & POOR'S STOCK PRICE INDEX -- OPENING, WEDNESDAY, FEB. 18 /PRN/
Next Article:GROCERY PRICES ARE HIGHER WHILE ENERGY PRICES CONTINUE TO FALL
Topics:


Related Articles
LILCO $363 MILLION 7.95 PERCENT PREFERRED STOCK RATED 'BBB-' BY FITCH -- FITCH FINANCIAL WIRE --
$2.5 BILLION CAPITAL SPENDING BUDGET FOR 1993 APPROVED BY ARCO BOARD OF DIRECTORS
PANCANADIAN PETROLEUM LTD. ANNOUNCES RESULTS
IDAHO POWER CO. $30 MILLION MEDIUM-TERM NOTES RATED 'A+' BY FITCH -- FITCH FINANCIAL WIRE --
COLUMBIA GAS ANNOUNCES 1994 CAPITAL EXPENDITURE PROGRAM
DiMARCO RESIGNS AS JENNY CRAIG PRESIDENT; ELLEN DESTRAY, SVP-OPS, NAMED COO
LAKEHEAD PIPE LINE PARTNERS, L.P.; SECOND QUARTER 1994 FINANCIAL RESULTS
IDAHO POWER CO. $490 MILLION 'A+' FIRST MORTGAGE BONDS AFFIRMED BY FITCH -- FITCH FINANCIAL WIRE --
MOCON ANNOUNCES SALES AND EARNINGS FOR THIRD QUARTER 1994
Project feasibility using breakeven point analysis.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters